Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press16810.17650/1726-9776-2011-7-2-92-95CLINICAL CASEКЛИНИЧЕСКИЙ СЛУЧАЙNEUROENDOCRINE CARCINOMA OF THE PROSTATE: A CASE REPORTНЕЙРОЭНДОКРИННЫЙ РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ (ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ)SkvortsovI. Ya.СкворцовИ. Я.
Russian Federation
igorsammi@mail.ruKamolovB. Sh.КамоловБ. Ш.
Russian Federation
igorsammi@mail.ruKhafizovK. O.ХафизовК. О.
Russian Federation
igorsammi@mail.ruPavlovskayaA. I.ПавловскаяА. И.
Russian Federation
igorsammi@mail.ruVishnevskayaYa. V.ВишневскаяЯ. В.
Russian Federation
igorsammi@mail.ruGutorovS. L.ГуторовС. Л.
Russian Federation
igorsammi@mail.ruFigurinK. M.ФигуринК. М.
Russian Federation
igorsammi@mail.ruMatveevV. B.МатвеевВ. Б.
Russian Federation
igorsammi@mail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowРОНЦ им. Н.Н. Блохина РАМН, Москва300620117292953007201430072014https://oncourology.abvpress.ru/oncur/article/view/168

Neuroendocrine carcinoma of the prostate belongs to the so-called small-cell neuroendocrine carcinomas and amounts to 1–2 % of all prostate malignancies. With allowance made for the low incidence of this pathology, the paper describes a case of high-grade neuroendocrine (small-cell) prostate cancer with an aggressive course.

Нейроэндокринный рак предстательной железы (РПЖ) относится к так называемым мелкоклеточным нейроэндокринным формам рака и составляет 1–2 % всех злокачественных опухолей предстательной железы. С учетом низкой встречаемости этой патологии приводится описание низкодифференцированного нейроэндокринного (мелкоклеточного) РПЖ с крайне агрессивным течением.

prostate cancerneuroendocrine cellsdifferentiationbiological markersрак предстательной железынейроэндокринные клеткидифференцировкабиологические маркеры1. Abrahamsson P.A. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate 1996;(Suppl 6):3–8.Abrahamsson P.A. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate 1996;(Suppl 6):3–8.2. Aprikian A.G., Cordon-Cardo C., Fair W.R. and Reuter V.E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinomas. Cancer 1993;71:3952–65.Aprikian A.G., Cordon-Cardo C., Fair W.R. and Reuter V.E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinomas. Cancer 1993;71:3952–65.3. VACURG. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011–7 .VACURG. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011–7 .4. Pretl K. Zur frage der endokrinie der menschlichen vorsteherdruse. Virch Arch Path Anat 1944;312:392–9.Pretl K. Zur frage der endokrinie der menschlichen vorsteherdruse. Virch Arch Path Anat 1944;312:392–9.5. Pearse A.G.E. The cytochemistry and ultrastructure of polypeptide hormoneproducing cells APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Citochem 1969;17:303–13.Pearse A.G.E. The cytochemistry and ultrastructure of polypeptide hormoneproducing cells APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Citochem 1969;17:303–13.6. Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 2002;95:1415–20.Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 2002;95:1415–20.7. Duran I., Berthold D.R., Pond G.R. et al. Meeting: 2007 Prostate Cancer Symposium. Abstract No:253 Neuroendocrine carcinoma of the prostate: Review of 14 cases at a single institution from 1988–2004.Duran I., Berthold D.R., Pond G.R. et al. Meeting: 2007 Prostate Cancer Symposium. Abstract No:253 Neuroendocrine carcinoma of the prostate: Review of 14 cases at a single institution from 1988–2004.8. di Sant’Agnese P.A., Davis N., Chen M. et al. Age-related changes in the neuroendocrine (endocrine-paracrine) cell population and the serotonin content of the guinea pig prostate. Laboratory Invest 1987;57:729–34.di Sant’Agnese P.A., Davis N., Chen M. et al. Age-related changes in the neuroendocrine (endocrine-paracrine) cell population and the serotonin content of the guinea pig prostate. Laboratory Invest 1987;57:729–34.9. Battaglia S., Casali A.M., Botticelli A.R. Agerelated distribution of endocrine cells in the humane prostate: a quantitative study. Virchows Arch 1994;424:165–8.Battaglia S., Casali A.M., Botticelli A.R. Agerelated distribution of endocrine cells in the humane prostate: a quantitative study. Virchows Arch 1994;424:165–8.10. di Sant’Agnese, P. A. Neuroendocrine differentiation in prostatic carcinoma. Cancer 1995;(Suppl 75):1850–9.di Sant’Agnese, P. A. Neuroendocrine differentiation in prostatic carcinoma. Cancer 1995;(Suppl 75):1850–9.11. Abrahamsson P.A., Waldstrom L.B., Almmets J. Peptide-hormone and serotoninimmunoreactive cells in normal and hyperplastic glands. Pathol Res Prat 1986;181:675–83.Abrahamsson P.A., Waldstrom L.B., Almmets J. Peptide-hormone and serotoninimmunoreactive cells in normal and hyperplastic glands. Pathol Res Prat 1986;181:675–83.12. Huttner W.B., Gerdes H.H., Rosa P. The granin (chromogranin/ secretogranin) family. TIBS 1991;16:27–30.Huttner W.B., Gerdes H.H., Rosa P. The granin (chromogranin/ secretogranin) family. TIBS 1991;16:27–30.13. Wu J.T., Wu T.L., Chang C.P. et al. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy. J Clin Lab Anal 1999;13:308–11.Wu J.T., Wu T.L., Chang C.P. et al. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy. J Clin Lab Anal 1999;13:308–11.14. Zifa E., Fillion G. 5-hydroxytriptamine receptors. Pharmacol Rev 1992;44:401–58.Zifa E., Fillion G. 5-hydroxytriptamine receptors. Pharmacol Rev 1992;44:401–58.15. Iwamura M., di Sant’Agnese P., Wu G. et al. Immunohistochemical localization or parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993;53:1724–6.Iwamura M., di Sant’Agnese P., Wu G. et al. Immunohistochemical localization or parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993;53:1724–6.16. Bonkhoff H., Stein U., Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995;26:167–70.Bonkhoff H., Stein U., Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995;26:167–70.17. Nakada S.Y., di Sant’Agnese P.A., Moynes R.A. et al. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993;53:1967–70.Nakada S.Y., di Sant’Agnese P.A., Moynes R.A. et al. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993;53:1967–70.18. More L.B., Buettner R., Ahmad N. et al. Prostate adenocarcinoma: cellular and molecular abnormalities. Cancer Control 2001;8(6):551–61.More L.B., Buettner R., Ahmad N. et al. Prostate adenocarcinoma: cellular and molecular abnormalities. Cancer Control 2001;8(6):551–61.19. Sciarra A., Mariotti G., Gentile V. et al. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU International 2003;91:438–45.Sciarra A., Mariotti G., Gentile V. et al. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU International 2003;91:438–45.20. Berruti A., Dogliotti L., Mosca A., Bellina M. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590–6.Berruti A., Dogliotti L., Mosca A., Bellina M. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590–6.21. Krijnen J.L., Bongdanowicz J., Seldenrijk C.A. et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158:171–4.Krijnen J.L., Bongdanowicz J., Seldenrijk C.A. et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158:171–4.22. Stein M., Bernstein Z., Abacioglu U. et al. Small cell (neuroendocrine) carcinomas of the prostate: etiology, diagnosis, prognosis and therapeutic implications – a retrospective study of 30 patients from rare cancer network. Am J Med Scienc 2008;336(6):478–88.Stein M., Bernstein Z., Abacioglu U. et al. Small cell (neuroendocrine) carcinomas of the prostate: etiology, diagnosis, prognosis and therapeutic implications – a retrospective study of 30 patients from rare cancer network. Am J Med Scienc 2008;336(6):478–88.23. Eble J.N. , Sauter G., Epstein J.I. et. al. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, 2004; p. 207–9.Eble J.N. , Sauter G., Epstein J.I. et. al. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, 2004; p. 207–9.